tesetaxel

Key projects include finalization of regulatory review for pivotal studies of tesetaxel and selection of a lead compound for IND filing from the oral gallium portfolio.

unknown title 2011

The Company is developing tesetaxel, a novel, orally absorbed taxane that is in the same class of drugs as paclitaxel and docetaxel.

unknown title 2011

Proceeds expected to enable initiation of global registration studies for tesetaxel

unknown title 2011

As the leading oral taxane in clinical development, tesetaxel has been evaluated in a broad program of completed or ongoing Phase 2a/Phase 2b clinical trials.

unknown title 2011

Proceeds of the financing will be used to accelerate development of the Company's small molecule pipeline, particularly late-stage registration studies of tesetaxel, the leading oral taxane in clinical development.

unknown title 2011

Genta has initiated a broad clinical program to evaluate the safety and efficacy of tesetaxel in patients with solid tumors.

TradingMarkets 2010

The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel.

TradingMarkets 2010

As a late Phase 2 oncology product, tesetaxel has demonstrated anticancer activity in its initial clinical trials, and the drug has not been associated with the severe infusion reactions that are linked with conventional taxanes.

TradingMarkets 2010

The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel.

TradingMarkets 2010

Genta has initiated a broad clinical program to evaluate the safety and efficacy of tesetaxel in patients with solid tumors.

TradingMarkets 2010